Sensitive Malignancy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New Efficacy Data Reinforces NEXTSTELLIS® Benefits Across Patient Populations Results presented at the 2021 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting News provided by Share this article Share this article GREENVILLE, N.C., April 30, 2021 /PRNewswire/ -- Mayne Pharma announced today results from two studies showing treatment with NEXTSTELLIS® (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets) demonstrated contraceptive efficacy and excellent cycle control across subgroups, including age, body mass index (BMI)[1] and prior contracepti...

GREENVILLE, N.C., April 16, 2021 /PRNewswire/ -- Mayne Pharma announced today that the U.S. Food and Drug Administration (FDA) has approved NEXTSTELLIS (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets) for the prevention of pregnancy. NEXTSTELLIS is the first and only contraceptive pill containing E4, a naturally occurring estrogen, now produced from a plant source, with a unique mechanism of action that offers potential advantages over other estrogens. "When speaking with patients about their contraceptive options, one of the most common concerns is side effects," said Mitchell...